Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 6;55(6):938-947.
doi: 10.3724/abbs.2023046.

Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance

Huiran Yue  1   2 , Xin Lu  1   2
Affiliations
Review

Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance

Huiran Yue et al. Acta Biochim Biophys Sin (Shanghai). .

Abstract

Antiangiogenic therapies, such as treatment with bevacizumab, display modest survival benefits in ovarian cancer (OC) patients. After a transient response, the upregulation of compensatory proangiogenic pathways and the adoption of alternative vascularization processes lead to the development of resistance. Considering the high mortality rate of OC, there is an urgent need to uncover the underlying mechanisms of antiangiogenic resistance for the development of novel and effective treatment strategies. Recent investigations have confirmed that metabolic reprogramming in the tumor microenvironment (TME) exerts an essential effect on tumor aggressiveness and angiogenesis. In this review, we provide an overview of the metabolic crosstalk between OC and the TME, highlighting the regulatory mechanisms underlying the development of antiangiogenic resistance. Metabolic interventions may interrupt this complex and dynamic interactive network, providing a promising therapeutic option to improve clinical outcome in OC patients.

Keywords: antiangiogenic therapy; metabolism; ovarian cancer; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

None
Figure 1
Key regulatory enzymes of the metabolic pathways in OC cells The main steps of glycolysis, OXPHOS, amino acid and lipid metabolism in OC cells, as well as key regulatory enzymes are summarized. SLC7A5: solute carrier family 7 member 5. GLS: glutaminase. GLUT: glucose transporter. HK2: hexokinase 2. PKM2: pyruvate kinase M2. PDH: pyruvate dehydrogenase. CD36: cluster of differentiation 36. FABP4: fatty acid binding protein 4. CPT1: Carnitine palmitoyltransferase 1. TCA: tricarboxylic acid cycle. FAO: fatty acid oxidation. OXPHOS: oxidative phosphorylation.
None
Figure 2
Overview of the metabolic crosstalk in the OC microenvironment On one hand, OC cells compete for the availability of glucose with CAFs and immune cells, which further reshapes their protumor and proangiogenic phenotypes. On the other hand, energy-rich metabolites mediate the interaction between the OC cells and the stromal cells, facilitating the metabolic synergy in the OC microenvironment.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. . 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ (Clinical research ed) 2020, 371: m3773 - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. . 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. - DOI - PubMed
    1. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. . 2011;365:2473–2483. doi: 10.1056/NEJMoa1104390. - DOI - PubMed
    1. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. . 2015;16:928–936. doi: 10.1016/S1470-2045(15)00086-8. - DOI - PMC - PubMed

MeSH terms